The broad-spectrum tyrosine kinase inhibitor dasatinib was found to arrest the cell cycle during G1 and S phases through increased p21 and retinoblastoma protein expression, which resulted in a robust tumour reduction in ARID1A-mutated ovarian cancer [110]. This evidence concerns the gene ARID1A and ovarian cancer.